BRPI0923862A2 - Compostos sulfonamida para o tratamento de distúrbios respiratórios - Google Patents

Compostos sulfonamida para o tratamento de distúrbios respiratórios

Info

Publication number
BRPI0923862A2
BRPI0923862A2 BRPI0923862-0A BRPI0923862A BRPI0923862A2 BR PI0923862 A2 BRPI0923862 A2 BR PI0923862A2 BR PI0923862 A BRPI0923862 A BR PI0923862A BR PI0923862 A2 BRPI0923862 A2 BR PI0923862A2
Authority
BR
Brazil
Prior art keywords
treatment
respiratory disorders
sulfonamide compounds
sulfonamide
compounds
Prior art date
Application number
BRPI0923862-0A
Other languages
English (en)
Inventor
Vidya Ramdos
Harry Finch
Craig Fox
Original Assignee
Pulmagen Therapeutics Inflammation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmagen Therapeutics Inflammation Ltd filed Critical Pulmagen Therapeutics Inflammation Ltd
Publication of BRPI0923862A2 publication Critical patent/BRPI0923862A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BRPI0923862-0A 2008-12-30 2009-12-23 Compostos sulfonamida para o tratamento de distúrbios respiratórios BRPI0923862A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3324CH2008 2008-12-30
PCT/GB2009/002951 WO2010076553A1 (en) 2008-12-30 2009-12-23 Sulfonamide compounds for the treatment of respiratory disorders

Publications (1)

Publication Number Publication Date
BRPI0923862A2 true BRPI0923862A2 (pt) 2015-07-28

Family

ID=41600475

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923862-0A BRPI0923862A2 (pt) 2008-12-30 2009-12-23 Compostos sulfonamida para o tratamento de distúrbios respiratórios

Country Status (21)

Country Link
US (1) US8362064B2 (pt)
EP (1) EP2379507B1 (pt)
JP (1) JP5555255B2 (pt)
CN (1) CN102272104B (pt)
AU (1) AU2009334597B2 (pt)
BR (1) BRPI0923862A2 (pt)
CA (1) CA2748331C (pt)
CY (1) CY1114798T1 (pt)
DK (1) DK2379507T3 (pt)
EA (1) EA019441B1 (pt)
ES (1) ES2442343T3 (pt)
HR (1) HRP20140022T1 (pt)
MX (1) MX2011007036A (pt)
NZ (1) NZ594157A (pt)
PL (1) PL2379507T3 (pt)
PT (1) PT2379507E (pt)
SG (1) SG172444A1 (pt)
SI (1) SI2379507T1 (pt)
SM (1) SMT201300156B (pt)
WO (1) WO2010076553A1 (pt)
ZA (1) ZA201104663B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10310294B2 (en) 2012-07-24 2019-06-04 Johnson & Johnson Vision Care, Inc. Thinned and flexible semiconductor elements on three dimensional surfaces
EP2868706A1 (en) 2013-10-29 2015-05-06 DyStar Colours Distribution GmbH Metal free acid dyes, methods for the production thereof and their use
UA124524C2 (uk) 2015-05-18 2021-10-05 Шеньян Сайнокем Аґрокемікалз Р&Д Ко., Лтд. Сполукa заміщеного піразолу, якa містить піримідиніл, її одержання і застосування

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
JPH0525045A (ja) 1991-07-18 1993-02-02 Tanabe Seiyaku Co Ltd 経皮吸収製剤
WO1993018007A1 (fr) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Nouveau derive de carbostyrile
EP1053227B1 (en) * 1998-01-29 2008-11-05 Amgen Inc. Ppar-gamma modulators
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
SI20116A (sl) 1998-12-02 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nov postopek za pripravo simvastatina in njegovih analogov
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB9908647D0 (en) 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
CN1426401A (zh) 2000-04-27 2003-06-25 贝林格尔英格海姆法玛公司 新的长效倍他米美类药物(betamimetics)其制备方法,及其作为药物组合物的用途
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
DE10346940B3 (de) 2003-10-06 2005-06-16 Schering Ag Substituierte Pentanole, ihre Verwendung zur Herstellung von Arzneimitteln speziell Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate
PT1305329E (pt) 2000-08-05 2007-12-24 Glaxo Group Ltd Éster s-fluorometílico do ácido 6.alfa.,9.alfa.-difluoro- 17.alfa.-(2-furanilcarboxil)oxi-11.beta.-hidroxi-16.alfa.-metil- 3-oxo-androsta-1,4-dieno-17-carbotióico como um agente antiinflamatório
WO2002013812A1 (en) 2000-08-17 2002-02-21 Pershadsingh Harrihar A Methods for treating inflammatory diseases
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP2004526720A (ja) 2001-03-08 2004-09-02 グラクソ　グループ　リミテッド βアドレナリン受容体のアゴニスト
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
MY137522A (en) 2001-04-30 2009-02-27 Glaxo Group Ltd Novel anti-inflammatory androstane derivatives.
ES2307751T3 (es) 2001-06-12 2008-12-01 Glaxo Group Limited Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano.
RU2312854C2 (ru) 2001-09-14 2007-12-20 Глаксо Груп Лимитед Производные фенэтаноламина для лечения респираторных заболеваний
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
WO2003042229A1 (en) 2001-11-12 2003-05-22 Glaxo Group Limited Non-aromatic heterocyclic esters of furan-2-one-esters of 17.beta.-carboxyl or 17.beta.-carbothio glucocorticoids
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
AU2002356759A1 (en) 2001-12-01 2003-06-17 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
AU2003202044A1 (en) 2002-01-15 2003-09-09 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
AU2003201693A1 (en) 2002-01-21 2003-09-02 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
DE60318193T2 (de) 2002-04-25 2008-12-04 Glaxo Group Ltd., Greenford Phenethanolaminderivate
EP1507754A1 (en) 2002-05-28 2005-02-23 Theravance, Inc. Alkoxy aryl beta-2 adrenergic receptor agonists
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
DE10246374A1 (de) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1440966A1 (en) 2003-01-10 2004-07-28 Pfizer Limited Indole derivatives useful for the treatment of diseases
OA12938A (en) 2002-10-11 2006-10-13 Pfizer Indole derivatives as beta-2 agonists.
AU2003298094A1 (en) 2002-10-22 2004-05-13 Glaxo Group Limited Medicinal arylethanolamine compounds
EP1556342B1 (en) 2002-10-28 2008-03-26 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
DE10253220A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
DE10258695A1 (de) 2002-12-16 2004-06-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neuer, langwirksamer Beta-agonist, Verfahren zu dessen Herstellung und dessen Verwendung als Arzneimittel
JP4606408B2 (ja) 2003-01-21 2011-01-05 メルク・シャープ・エンド・ドーム・コーポレイション 選択的グルココルチコイド受容体調節物質としての１７−カルバモイルオキシコルチゾル誘導体
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
JP4516064B2 (ja) 2003-04-04 2010-08-04 ノバルティス アーゲー 気道疾患の処置のためのキノリン−２−オン誘導体
EP1477167A1 (en) 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
EP1626970B1 (en) 2003-05-28 2009-07-08 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
EP1633714B1 (en) 2003-06-04 2008-01-23 Pfizer Limited 2-amino-pyridine derivatives as beta-2 adrenoreceptor agonists
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
WO2005003098A1 (de) 2003-07-01 2005-01-13 Schering Aktiengesellschaft Heterozyklisch substituierte pentanol-derivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
BRPI0414536A (pt) 2003-09-17 2006-11-07 Novartis Ag compostos orgánicos
WO2005033121A2 (en) 2003-10-03 2005-04-14 King Pharmaceuticals Research & Development, Inc. Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs
PL1670458T3 (pl) 2003-10-08 2007-05-31 Bayer Schering Pharma Ag 1-amino-2-hydroksy-podstawione pochodne tetrahydronaftalenu, sposób ich wytwarzania i ich zastosowanie jako środków hamujących zapalenie
DE10347385A1 (de) 2003-10-08 2005-05-12 Schering Ag Umgelagerte Pentanole, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
GB0323701D0 (en) 2003-10-09 2003-11-12 Glaxo Group Ltd Formulations
GB0324654D0 (en) 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0324886D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0328490D0 (en) 2003-12-09 2004-01-14 Glaxo Group Ltd Medicinal compounds
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
US7807046B2 (en) 2003-12-19 2010-10-05 Shell Oil Company Systems, methods, and catalysts for producing a crude product
DE102004001413A1 (de) 2004-01-09 2005-08-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Hydroxymethyl-4-Hydroxy-Phenyl-Derivate zur Behandlung von chronisch obstruktiver Lungenerkrankung
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
PT1708991E (pt) 2004-01-22 2007-12-14 Pfizer Derivados de sulfonamida para o tratamento de doenças
AU2005214154B2 (en) 2004-01-22 2008-01-24 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases
DE102004003428A1 (de) 2004-01-23 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel
CA2552871A1 (en) 2004-02-14 2005-08-25 Boehringer Ingelheim International Gmbh Novel, sustained-action beta-2-agonists and their use as medicaments
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
EP1577292A1 (en) 2004-03-17 2005-09-21 Pfizer Limited Phenylaminoethanol derivatives as beta2 receptor agonists
EP1577306A1 (de) 2004-03-17 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
HN2004000023A (es) 2004-03-22 2007-11-23 Mars Inc Mascadura para animales
AU2005225638A1 (en) 2004-03-23 2005-10-06 Pfizer Inc. Compounds for the treatment of diseases
WO2005092841A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
AU2005225632B2 (en) 2004-03-23 2011-08-04 Pfizer Inc. Formamide derivatives useful as adrenoceptor
WO2005092860A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Compounds for the treatment of diseases
EP1595873A1 (de) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen
WO2005110990A1 (de) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen
DE102004024451A1 (de) 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
DE102004024454A1 (de) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US7402673B2 (en) 2004-06-03 2008-07-22 Theravance, Inc. Diamine β2 adrenergic receptor agonists
US7317023B2 (en) 2004-07-21 2008-01-08 Theravance, Inc. Diaryl ether β2 adrenergic receptor agonists
WO2006016245A1 (en) 2004-08-05 2006-02-16 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2006031556A2 (en) 2004-09-10 2006-03-23 Theravance. Inc. Amidine substituted aryl aniline compounds
DE102004045648A1 (de) 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
WO2006051373A1 (en) 2004-11-12 2006-05-18 Pfizer Limited Compounds for the treatment of diseases
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
MX2011007036A (es) 2011-07-20
CN102272104A (zh) 2011-12-07
EA201101014A1 (ru) 2012-01-30
CA2748331A1 (en) 2010-07-08
US20120041043A1 (en) 2012-02-16
PT2379507E (pt) 2014-01-21
AU2009334597B2 (en) 2015-07-16
US8362064B2 (en) 2013-01-29
HRP20140022T1 (hr) 2014-02-14
WO2010076553A1 (en) 2010-07-08
PL2379507T3 (pl) 2014-03-31
CA2748331C (en) 2016-08-02
NZ594157A (en) 2013-07-26
EA019441B1 (ru) 2014-03-31
AU2009334597A1 (en) 2011-07-21
EP2379507A1 (en) 2011-10-26
CY1114798T1 (el) 2016-12-14
JP2012514027A (ja) 2012-06-21
HK1158626A1 (en) 2012-07-20
DK2379507T3 (da) 2014-01-27
SG172444A1 (en) 2011-07-28
EP2379507B1 (en) 2013-10-16
ES2442343T3 (es) 2014-02-11
SMT201300156B (it) 2014-03-07
SI2379507T1 (sl) 2014-02-28
CN102272104B (zh) 2014-07-09
ZA201104663B (en) 2012-10-31
JP5555255B2 (ja) 2014-07-23

Similar Documents

Publication Publication Date Title
BRPI0918527A2 (pt) compostos para o tratamento de disturbios do cns
PT3415535T (pt) Nanocorpos tm aperfeiçoados para o tratamento de distúrbios mediados por agregação
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
BRPI0819241A2 (pt) Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BR112012013260A2 (pt) dispositivo usado para o tratamento de rinite através de iluminação bioestimulativa
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BRPI0911923A2 (pt) dispositivos filamentosos para o tratamento de defeitos vasculares
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
BR112012012451A2 (pt) dispositivo de compressão graduado para o tratamento de desordens circulatórias
DK2222272T3 (da) Behandling af luftvejssygdom
PT2627345E (pt) Formulações para o tratamento de distúrbios das vias respiratórias superiores
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0911577A2 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI1013245A2 (pt) "composto para o tratamento de distúrbios metabólicos"
PT2236149E (pt) Composição medicinal para o tratamento de doenças infeciosas respiratórias
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
BRPI0917440A2 (pt) composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho
BRPI0915428A2 (pt) derivados de benzoxazinona atuando como agonistas adrenorreceptor beta2 para o tratamento de distúrbios respiratórios
HUE033690T2 (hu) Terápiás szer hangulatzavarokra
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.